Tell Us What You Think

Rate your Quintiles.com experience

Subscribe to Email Based on Your Interests

Set preferences

Information Library

Cost control/reduction - Phase I/IIa

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by: Most Recent
  • Title
  • QUINTILES INCREASES CAPACITY TO SUPPORT EUROPEAN CLINICAL TRIALS


    September 24, 2009 - Quintiles Transnational Corp. today announced the opening of an expanded regional facility near Edinburgh, Scotland. Located within the Alba Campus, a research and development center near Edinburgh, the 115,000-square-foot building hosts more than 500 employees and has space for Quintiles Clinical Development Services, including Project Management, Regulatory Affairs and Data Management.

  • Phase One Services: Professor Anders E. Grahnen

    July 24, 2009
    With the current high costs of drug development, it's crucial that you can establish the potential success of your agent before the end of Phase II. Our market-leading expertise in biomarkers and specialist techniques can help you do just that.

  • Phase One Services: Dr. Brock G. Guernsey

    July 24, 2009
    Why wait two months to see your data and delay critical decisions when we can deliver your data within a week using electronic bedside data entry? Consider what a 2-month delay means to your drug's development plan? Whether you've done preclinical work and need a rapid Proof of Concept study or are looking for a benchmark of how your drug performs in a specific disease state, we can help.

  • Phase One Services: Dr. Elizabeth Allen

    July 24, 2009
    In 2008 TUFTS reported that it costs over $1 billion to develop a new biopharmaceutical product. Half of this investment occurs in the later stages of testing. Thankfully at Quintiles, we provide accurate and correct Phase I and IIa data quickly. We can help you make smart, safe decisions earlier to avoid repeating costly studies later.

  • Phase One Services: Dr. Philip T. Leese

    July 24, 2009
    At Quintiles, we appreciate the data collection from the clinic as one of the most important parts of a study process. To deliver quality data on time, we ensure that all clinical conduct is consistent, efficient and accurate to your protocol. But to do this we also need to recruit the right volunteers. Our database of clearly defined volunteers means we can quickly call upon participants for student specific screening, saving you time and money. What's more, we also use a range of recruitment methods to keep the database up to date with interested volunteers.

  • Phase One Services: Professor Timothy G.K. Mant

    July 24, 2009
    You can only have total confidence in the integrity and analysis of results of you're sure your study has been conducted in exceptional clinical conditions. So it's absolutely crucial that your Phase I/IIa partner places ethics, safety and expert clinical conduct at the heart of all their activities.

  • Clinical Development Services

    June 18, 2009
    Find out how large pharmaceutical companies and emerging biotech move products past each development milestone.

  • QT Population Modeling and Simulation Case Study

    June 15, 2009
    The importance of determining the most strategic Phase I/IIa study conducted by leading specialists shouldn’t be understated. Gain insight into QT and Population Modeling & Simulation.